Download MendeleyMyomedin scaffold variants targeted to 10E8 HIV-1 broadly neutralizing antibody mimic gp41 epitope and elicit HIV-1 virus-neutralizing sera in mice.
Kuchar, M., Kosztyu, P., Daniel Liskova, V., Cerny, J., Petrokova, H., Vroblova, E., Maly, M., Vankova, L., Krupka, M., Raskova Kafkova, L., Turanek Knotigova, P., Duskova, J., Dohnalek, J., Masek, J., Turanek, J., Raska, M., Maly, P.(2021) Virulence 12: 1271-1287
- PubMed: 33993840
- DOI: https://doi.org/10.1080/21505594.2021.1920251
- Primary Citation of Related Structures:
6T3O - PubMed Abstract:
One of the proposed strategies for the development of a more efficient HIV-1 vaccine is based on the identification of proteins binding to a paratope of chosen broadly neutralizing antibody (bNAb) that will mimic cognate HIV-1 Env (glyco)protein epitope and could be used as potent immunogens for induction of protective virus-neutralizing antibodies in the immunized individuals. To verify this "non-cognate ligand" concept, we developed a highly complex combinatorial library designed on a scaffold of human myomesin-1 protein domain and selected proteins called Myomedins specifically binding to variable regions of HIV-1 broadly neutralizing antibody 10E8. Immunization of mice with these Myomedin variants elicited the production of HIV-1 Env-specific antibodies. Hyperimmune sera bound to Env pseudotyped viruses and weakly/moderately neutralized 54% of tested clade A, B, C, and AE pseudotyped viruses variants in vitro . These results demonstrate that Myomedin variants have the potential to mimic Env epitopes and could be used as potential HIV-1 vaccine components.
Organizational Affiliation:
Laboratory of Ligand Engineering, Institute of Biotechnology of the Czech Academy of Sciences, BIOCEV Research Center, Vestec, Czech Republic.
